

Supporting Information

Novel Aryltriazole Acyclic C-Azanucleosides as Anticancer Candidates

Yanhua Zhang^{a#}, Yun Lin^{a#}, Qianqian Hou^a, Xi Liu^a, Sabrina Pricl^{b,c}, Ling Peng^d, Yi
Xia^{a*}

^a Chongqing Key Laboratory of Natural Product Synthesis and Drug Research,
School of Pharmaceutical Sciences, Chongqing University, Chongqing, 401331,
China.

^b Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA,
University of Trieste, Trieste, Italy

^c Department of General Biophysics, Faculty of Biology and Environmental
Protection, University of Lodz, 90-236 Lodz, Poland

^d Aix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de
Marseille (CINaM), UMR 7325, Equipe Labellisé par La Ligue, 13288 Marseille,
France.

*Corresponding Author

Dr. Yi XIA, Email: yixia@cqu.edu.cn

These authors contribute equally to this work

Table of Contents

Figure S1	S3
Figure S2	S4
Figure S3	S5
Figure S4	S6
Figure S5	S7
Table S1	S8
Table S2	S10
Table S3	S12
¹ H NMR, ¹³ C NMR spectra	S13
HPLC spectra	S39

Figure S1. The UV-Visible spectrum of **Ia**, **If**, **Ig**, **Ii**, **Ij**, **Ik**, **II** and **II** in MeOH (50 μ M) was recorded on Agilent Cary 60 UV-Vis Spectrophotometer within the spectral region of 200-400 nm.




Figure S2. 1D NOESY spectra of **Ia**, **If**, **Ig**, **Ij** and **Ik** dissolved in CDCl₃ (20mg/mL) using a 800 ms NOESY mixing time was recorded on Agilent DD2 600-MR. The proton (H*) in triazole ring was selectively irradiated and the strong NOE at 7.6 ppm (H_A) and 4.0 ppm (H_B) was observed.




Figure S3. Compound **Ig** predominantly induced apoptosis in cancer cells with negligible necrosis. (A) Panc-1 cells were treated with different doses of **Ig** for 48 h and the percentage of cells undergoing apoptosis (Annexin V-positive cells) and necrosis (PI-positive cells) was determined with flow cytometry. Untreated cells were used as the reference control. (B) Compound **Ig** efficiently induced the cleavage of PARP and downregulation of BCL-2 in Panc-1 cells. BCL-2 and PARP protein levels after treatment with different concentrations of compound **Ig** were analyzed by use of western blotting, with β -actin as the reference. (C) Necrosis induced by different concentrations of **Ig** in Panc-1 cells was assessed by LDH assays.




Figure S4. Compound **Ic** and **Ik** could not induce apoptosis or inhibit the expression of HSF1, HSP27, HSP70, HSP90 α and eIF4E in Panc-1 cells. (A) Panc-1 cells were treated with **Ic** and **Ik** (15 μ M) for 48 h and the percentage of cells undergoing apoptosis (Annexin V-positive cells) and necrosis (PI-positive cells) was determined with flow cytometry. Untreated cells were used as the reference control. (B) Panc-1 cells were treated with **Ic** and **Ik**. Then the BCL-2 and PARP protein levels after treatment were analyzed by western blotting, with β -actin as the reference. (C) Necrosis induced by different concentrations of **Ic** and **Ik** in Panc-1 cells was assessed by LDH assays. (D) Panc-1 cells were treated with **Ic** and **Ik**. Then the protein levels of HSF1, HSP27, HSP70, HSP90 α and eIF4E were analyzed by western blotting, with β -actin as the reference.




Figure S5. Compound **Ig** efficiently inhibited the expression of HSF1, HSP27, HSP70, HSP90 α and eIF4E in Panc-1 cells (B). Panc-1 cells were treated with **Ig** at indicated concentrations. Protein levels of HSF1, HSP27, HSP70, HSP90 α and eIF4E were then analyzed by western blotting, with β -actin as the reference.















Table S1. Optimized structures and the corresponding values of the geometrical parameters for compounds **Ia-II** as obtained from Density Functional (DFT) calculations performed at the B3LYP/6-311++G(d,p) level. Molecular structures are shown as atom-colored sticks-and-balls (C, gray; O, red; N, blue; H, white; F, light cyan; Cl, light green; Br, dark red).

Compound	Structure	Dihedral angle 1 (°) ^a	Dihedral angle 2 (°) ^b	H-H distance (Å) ^c
Ia		178.1	-178.2	2.21
Ib		178.7	-178.9	2.22
Ic		177.8	-177.6	2.21
Id		178.3	-178.1	2.21
Ie		177.4	-177.9	2.23
If		177.4	-177.2	2.23
Ig		177.3	-177.1	2.23
Ih		177.2	-177.3	2.23
Ii		178.4	-178.9	2.27
Ij		179.0	-178.6	2.24
Ik		178.6	-178.6	2.33







<p style="text-align: center;">II</p>		<p style="text-align: center;">178.9</p>	<p style="text-align: center;">-178.4</p>	<p style="text-align: center;">2.27</p>
<p>^aAtoms involved in dihedral angle 1 (N2-C6-C7-C8) are shown in orange for Ik as an example</p>				
<p>^bAtoms involved in dihedral angle 2 (N2-C6-C11-C10) are shown in orange for Ik as an example</p>				
<p>^cAtoms involved in H-H distance are shown in orange for Ik as an example</p>				

Table S2. Comparison between experimental (X-ray) and calculated (B3LYP/6-311++G(d,p)) values of the main structural parameters for compound **Ik**. The first row shows the X-ray derived (left) and DFT-optimized (right) molecular structure of **Ik** (atom color code: C, gray; O, red; N, blue; Cl, light green; H, white).



					
Atoms	Experimental	Calculated	Atoms	Experimental	Calculated
Bond length (Å)			Bond length (Å)		
C11-C9	1.742(5)	1.76(0)	C6-C7	1.378(6)	1.39(0)
N2-N3	1.347(5)	1.35(1)	N4-C4	1.363(6)	1.36(1)
N2-C6	1.426(5)	1.44(2)	C5-C4	1.356(6)	1.36(0)
N2-N5	1.352(6)	1.35(8)	C3-C4	1.483(6)	1.49(0)
O1-C1	1.408(6)	1.41(0)	C10-C9	1.377(6)	1.37(3)
N1-C3	1.465(5)	1.48(4)	C10-C11	1.386(7)	1.38(2)
N1-C2	1.460(5)	1.48(3)	C9-C8	1.362(7)	1.37(3)
N3-N4	1.315(6)	1.33(0)	C2-C1	1.512(6)	1.52(3)
C6-C11	1.385(6)	1.39(2)	C7-C8	1.372(7)	1.38(1)
Bond angle (°)			Bond angle (°)		
N3-N2-C6	120.6(4)	120.5(1)	C5-C4-N4	107.5(4)	108.8(2)
N3-N2-C5	109.7(4)	108.5(7)	C5-C4-C3	130.3(4)	129.6(9)
C5-N2-C6	129.7(4)	130.8(9)	C9-C10-C11	118.7(5)	119.9(7)
C2-N1-C3	111.5(4)	111.8(6)	C10-C9-Cl21	118.7(4)	119.9(6)
N4-N3-N2	107.3(4)	107.9(3)	C8-C9-C11	120.3(4)	120.0(3)
C11-C6-N2	119.4(4)	119.8(1)	C8-C9-C10	121.1(4)	120.0(1)
C7-C6-N2	120.3(4)	120.1(4)	N1-C2-C1	110.1(4)	112.3(4)
C7-C6-C11	120.3(4)	120.0(4)	C6-C11-C10	120.0(4)	119.9(8)
N3-N4-C4	109.4(4)	107.4(4)	C8-C7-C6	119.2(5)	119.9(9)
N2-C5-C4	106.2(4)	107.2(0)	C9-C8-C7	120.6(4)	120.0(0)
N1-C3-C4	111.5(4)	111.7(3)	O1-C1-C2	111.6(4)	112.3(2)
N4-C4-C3	122.1(4)	121.3(1)			
Torsion angle (°)			Torsion angle (°)		
Cl11-C9-C8-C7	-177.5(4)	-179.3(9)	C6-N2-N3-N4	178.2(3)	178.8(1)
N2-N3-N4-C4	-0.5(6)	-0.4(8)	C6-N2-C5-C4	-177.9(4)	-178.0(9)
N2-C6-C11-C10	-178.3(4)	-178.6(1)	C6-C7-C8-C9	0.5(7)	0.08(9)
N2-C6-C7-C8	177.4(4)	178.6(7)	C5-N2-N3-N4	1.0(6)	0.5(1)
N2-C5-C4-N4	0.7(5)	0.8(4)	C5-N2-C6-C11	164.2(5)	165.1(0)
N2-C5-C4-C3	177.7(4)	176.3(2)	C5-N2-C6-C7	-15.1(6)	-15.6(8)
N1-C3-C4-N4	-21.6(6)	-23.2(5)	C3-N1-C2-C1	-167.2(4)	-168.1(3)
N1-C3-C4-C5	161.8(4)	161.5(3)	C10-C9-C8-C7	1.7(7)	0.6(4)
N1-C2-C1-O1	58.5(5)	58.7(5)	C9-C10-C11-C6	1.2(7)	0.7(4)



N3-N2-C6-C11	-12.4(6)	-13.2(0)	C2-N1-C3-C4	172.4(3)	171.4(4)
N3-N2-C6-C7	168.4(5)	166.0(2)	C11-C6-C7- C8	-1.8(7)	-0.5(5)
N3-N2-C5-C4	-1.1(5)	-0.9(8)	C11-C10-C9-C11	176.7(4)	179.4(6)
N3-N4-C4-C5	-0.1(6)	-0.094(4)	C11-C10-C 9-C8	-2.5(7)	-0.5(8)
N3-N4-C4-C3	-177.4(4)	-176.7(0)	C7-C6-C11-C10	1.0(7)	0.6(1)



Table S3. *In silico* predicted main pharmacokinetic parameters of compounds **Ia-II**.


Cpd.	MW ^a	HBA ^b	HBD ^c	logP ^d	logS ^e	PSA ^f	BBB score ^g	Rule of 5 violation	Drug likeness
Rule of 5	<500	≤10	≤5	≤5	≤5	-	-	≤1	-
Ia	232.13	4	2	0.83	-0.94	55.63	4.44	0	-0.53
Ib	260.16	4	2	1.81	-1.41	55.63	4.59	0	-0.47
Ic	288.20	4	2	2.86	-2.99	55.63	4.69	0	-0.37
Id	316.23	4	2	3.87	-3.85	55.63	4.76	0	-0.37
Ie	358.27	4	2	5.39	-5.32	55.63	4.79	1	-0.37
If	386.30	4	2	6.40	-6.04	55.63	4.78	1	-0.37
Ig	414.34	4	2	7.41	-6.12	55.63	4.74	1	-0.37
Ih	442.37	4	2	8.43	-6.23	55.63	4.70	1	-0.37
Ii	286.10	4	2	1.33	-1.13	55.63	4.69	0	-0.82
Ij	284.13	5	2	0.35	-1.44	63.18	4.06	0	-0.42
Ik	252.08	4	2	0.98	-1.60	55.63	4.54	0	-0.20
II	286.03	4	2	1.23	-0.91	55.63	4.71	0	-0.62

^aMolecular weight; ^bnumber of hydrogen bond acceptors; ^cnumber of hydrogen bond donors; ^dlogarithm of n-octanol/water partition coefficient; ^elogarithm of water solubility (in log(mol/L)); ^fpolar surface area; ^gBlood-brain barrier score: 6 = High; 0 = low.


















1a






















































































VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-03 10-50-51\036-0901.D)




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-04 09-49-02\036-1501.D)




Method 2




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-01 16-03-48\021-0101.D)




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-04 09-49-02\021-0101.D)




VWD1 A, Wavelength=254 nm (ZYH\2019-06-01 12-27-06.D)




Method 1



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-03 19-02-07\016-0601.D)





Method 2



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-01 17-27-19\022-0101.D)

#	[min]		[min]	[mAU*s]	[mAU]	%
1	16.828	BV	0.2641	39.25198	2.37189	0.1448
2	17.195	VV	0.2820	48.90801	2.52504	0.1804
3	17.928	VV	0.3052	148.41342	6.78524	0.5473
4	18.353	VB	0.2538	2.67349e4	1660.88879	98.5964
5	21.045	BB	0.4314	75.24069	2.67293	0.2775
6	22.085	BB	0.4422	68.77412	2.32432	0.2536



Method 1



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-04 09-49-02\022-0201.D)

#	[min]		[min]	[mAU*s]	[mAU]	%
1	17.407	BB	0.0959	42.17682	6.56727	0.2339
2	17.749	BV	0.0949	1.74643e4	2833.02490	96.8701
3	18.069	VV	0.1323	234.51511	24.35652	1.3008
4	18.991	BB	0.1315	41.86037	5.05896	0.2322
5	19.464	BB	0.1198	98.82977	12.42097	0.5482
6	19.912	VV	0.1522	146.89954	13.57878	0.8148



Method 2



VWD1 A, Wavelength=254 nm (ZWZ2019-06-01 10-58-25.D)

#	[min]		[min]	[mAU*s]	[mAU]	%
1	16.822	BV	0.2380	57.32187	3.73528	0.2923
2	17.192	VV	0.3732	128.24361	4.87066	0.6540
3	19.387	BV	0.2000	112.68510	8.48284	0.5747
4	19.854	VB	0.2341	1.91751e4	1270.57324	97.7873



Method 1



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-03 19-02-07\014-0401.D)

#	[min]		[min]	[mAU*s]	[mAU]	%
1	1.492	BV	0.1060	172.78169	23.70901	0.8194
2	17.398	BV	0.2936	103.46705	5.21143	0.4907
3	18.456	BV	0.1149	54.85160	6.96024	0.2601
4	18.776	VV	0.2318	2.06827e4	1183.79102	98.0815
5	19.867	VB	0.2065	40.84987	2.70069	0.1937
6	20.981	VV	0.2935	32.60613	1.74086	0.1546



Method 2



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-01 17-27-19\023-0201.D)

#	[min]		[min]	[mAU*s]	[mAU]	%
1	13.730	BB	0.2133	59.29742	4.34393	0.2752
2	17.252	BV	0.2697	31.93840	1.86542	0.1482
3	17.949	VV	0.3060	36.50195	1.71702	0.1694
4	19.959	BV	0.3337	148.16371	6.83958	0.6876
5	20.991	VV	0.3150	2.12711e4	996.72205	98.7195



Method 1



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-04 09-49-02\023-0301.D)

#	[min]		[min]	[mAU*s]	[mAU]	%
1	9.550	BV	0.1179	157.90239	20.71993	1.0482
2	17.440	VV	0.1468	24.00167	2.41732	0.1593
3	18.989	BV	0.1394	89.70851	9.56607	0.5955
4	19.448	BV	0.1004	1.44378e4	2203.34155	95.8453
5	19.898	VV	0.1960	319.25705	24.49640	2.1194
6	20.368	BB	0.1874	34.98446	3.05905	0.2322



Method 2



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-01 17-27-19\024-0301.D)

#	[min]		[min]	[mAU*s]	[mAU]	%
1	15.891	BB	0.2316	45.42381	2.93477	0.2557
2	17.834	BB	0.3030	113.98190	5.65813	0.6416
3	20.017	VB	0.3708	48.42418	2.15827	0.2726
4	21.016	BV	0.4969	365.86841	10.46394	2.0595
5	22.452	VV	0.4081	1.71916e4	603.98199	96.7707



Method 1



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-04 09-49-02\024-0401.D)

#	[min]	[min]	[min]	[mAU*s]	[mAU]	%
1	17.293	VB	0.1687	74.22266	6.15238	0.5062
2	18.198	VV	0.1635	33.85910	2.89467	0.2309
3	18.990	BB	0.1219	26.85925	3.48595	0.1832
4	19.450	BV	0.1951	345.94815	26.54263	2.3592
5	19.993	VV	0.1137	1.41829e4	1886.20056	96.7206


Method 2




VWD1 A, Wavelength=254 nm (ZYH\2019-05-31 17-09-01.D)

#	[min]		[min]	[mAU*s]	[mAU]	%
1	11.021	BB	0.1880	36.88477	3.05239	0.1980
2	16.834	BV	0.2815	42.22526	2.21399	0.2266
3	17.224	VB	0.2975	88.62632	4.62699	0.4756
4	21.085	BB	0.3243	44.18845	2.19096	0.2372
5	22.187	BB	0.3845	65.28121	2.61316	0.3504
6	23.365	BV	0.3844	236.39168	8.39860	1.2687
7	23.666	VV	0.2826	172.78238	8.93348	0.9273
8	24.402	VB	0.4883	1.79466e4	527.01984	96.3163

Method 1





1h




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-04 20-15-25\038-0201.D)

#	[min]		[min]	[mAU*s]	[mAU]	%
1	18.257	BV	0.1343	52.39722	6.03583	0.2568
2	18.387	VB	0.1107	41.96924	5.40082	0.2057
3	18.991	BB	0.1263	74.50204	9.21969	0.3651
4	19.469	VB	0.1123	179.31879	24.54010	0.8788
5	19.921	VV	0.1582	301.92313	26.84204	1.4797
6	20.195	VV	0.1144	104.36230	13.03116	0.5115
7	20.643	VB	0.1354	1.96504e4	2154.62598	96.3025


Method 2




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-01 17-27-19\027-0601.D)




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-04 09:49:02\027-0701.D)




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-03 10-50-51\028-0101.D)




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-04 09-49-02\028-0801.D)




Method 2




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-01 17-27-19\026-0501.D)




VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-04 09-49-02\026-0601.D)



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-01 13-08-14\015-0101.D)



Method 1



VWD1 A, Wavelength=254 nm (FY190425DEF_LC.SFY 2019-06-03 19-02-07\012-0201.D)

